TFF Pharmaceuticals Q2 2024 Earnings Report $0.06 0.00 (0.00%) As of 03/28/2025 Earnings History TFF Pharmaceuticals EPS ResultsActual EPS-$1.22Consensus EPS -$1.70Beat/MissBeat by +$0.48One Year Ago EPSN/ATFF Pharmaceuticals Revenue ResultsActual Revenue$0.65 millionExpected Revenue$0.15 millionBeat/MissBeat by +$500.00 thousandYoY Revenue GrowthN/ATFF Pharmaceuticals Announcement DetailsQuarterQ2 2024Date8/14/2024TimeN/AConference Call ResourcesTFFP Earnings History Remove Ads TFF Pharmaceuticals Earnings HeadlinesTFF Pharmaceuticals approves dissolution planMarch 8, 2025 | uk.investing.comTFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC DeregistrationFebruary 6, 2025 | prnewswire.comRevealed: The Chip Stock Redefining AI as We Know ItIn this urgent presentation, Wall Street's so-called "AI Oracle" unveils the name of a small American tech firm poised to disrupt the $1 trillion semiconductor industry. He's the same expert who spotted Apple before the iPhone, Amazon before it dominated retail, and Google before it became a verb. Back then, Wall Street shrugged. They're doing it again—ignoring his latest prediction. But according to his research, what we've seen from AI so far is just the beginning. The real boom is still ahead.April 1, 2025 | InvestorPlace (Ad)U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%November 15, 2024 | msn.comTFF Pharmaceuticals Shares Fall 66%; Company to Wind DownNovember 15, 2024 | marketwatch.comTFF Pharmaceuticals terminates employees, to wind down operationsNovember 15, 2024 | markets.businessinsider.comSee More TFF Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TFF Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TFF Pharmaceuticals and other key companies, straight to your email. Email Address About TFF PharmaceuticalsTFF Pharmaceuticals (NASDAQ:TFFP), a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.View TFF Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
